In this study, we isolated and evaluated BSCs derived from breast cancer patients, and explored the suitability of BSCs as sources of antigens for DC vaccination again human BSCs, with the aim of achieving BSC targeting and enhanced antitumor immunity. We found that 
Introduction
In recent years, there are numerous evidences that have been validated that breast cancer contains a hierarchy of heterogeneous cell populations with different biological properties and that the capability to sustain tumor formation and growth exclusively resides, termed cancer stem cells (CSCs) [1] [2] [3] . These studies have shown that CSCs are responsible for tumor formation and progression and, interestingly, that they are endowed with stem/progenitor cell properties; in particular, tumor stem cells share the key feature of self-renewal [4] [5] . Al-Hajjet al. [6] agents and radiation in breast cancer [4, 7] .
The identification of human BSCs presents a novel legend for the development of breast cancer treatments. The stem cell phenotype of breast cancer cells and their limited number within tumor tissues may account for their capability to escape conventional therapies, thus leading to disease relapse although the primary lesion is eradicated [4, 7] and are postulated to be the cells responsible for the relapse and pro--gression of cancers after such therapies.
In an analogous fashion, the BSC phenomenon may adversely affect the development of effective immune--therapies for breast cancer. These therapies have involved targeting breast cancer cells that express differentiated tumor antigens which may be selectively expressed on differentiated tumor cells [8, 9] . However, BSCs that do not express these antigens may thus escape these immune surveillance.
Clinical trials to treat breast cancer using dendritic cells (DCs) vaccine [10, 11] have shown therapeutic efficacy for vaccines [12] . Human tumors are composed of heterogeneous tumor cell clones that differ with respect to proliferation, differentiation, and ability to initiate daughter tumors [13] . The apability to target BSCs with current immune methods may be a critical cause for therapeutic failures.
On this basis, we isolated and assessed stem cell phenotype and tumorigenicity of BSCs which derived from patients of Cell Disrupter (Safer, Nanjing, China).
Tumor antigen protein concentrations were determined using Bio-Rad Protein Assay reagents (Hercules, CA).
T-cell stimulation and cytotoxic T-cell assays against BSCs
The non-adherent lymphocytes were stimulated with autologous DCs loaded with BSC or adherent cells (BAC) lysates at the ratio of 5:1 (the BSCs lysates and DCs were co-cultured overnight before they were seeded with lymphocytes).
Interleukin-2 (IL-2; 300 IU/ml) was added to the cultures the next day and every 3 days thereafter. The lymphocytes were days, and its tumorigenic capacity is much lower than the mammospheric group (2/10) ( Table 2 and Figure 5A , 5B ). Figure   5C , 5D). It indicated that these enriched mammospheric cells have a strong invasive and metastatic capacity. Figure   4C , and the cytotoxicity of BAC-CTL was significantly higher than of BSC-CTL against the adherent cells (*P＜0.05) in Figure 4D . (Fig. 5A , 5B). The spot counts was 52 and 31 spots which were produced in BSC-CTL and BAC-CTL against the mammospheric cells at E:T=10:1 respectively. The IFN-γ production of BSC-CTL were avidently higher than of BAC-CTL by spot counts (*P ＜0.05) in Figure 5D . Moreover the IFN-γ ELISPOT results of BSC-CTL were avidently higher than BAC-CTL by well areas coverd (*P＜0.05) in Figure 5E . The IFN-γ production of both BSC-CTL and BAC-CTL were avidently higher than
Blank-CTL at apot counts and well areas coverd respectively (*P ＜ 0.01 and *P ＜ 
DISCUSSION
Large numbers of proofs had supported the notion that a small subpopulation of breast cancer stem-like cells is responsible for cancer progression [15] , therapy resistance [16] , and relapse [17] . [18, 19] . In addition, The BSCs highly express CD133+ phenotype which have the capacity of transdifferentiation and contributed to vasculogenic mimicry (VM) in triple-negative breast cancer [3] . Sunitinib induced hypoxia in TNBCs, and Twist1 expression induced by hypoxia accelerated VM by increasing population of CD133+ cells [20] . VM was pivotal factor and responsible for invasive and metastatic capacity of breast cancer.
To inhibit breast cancer relapse more very strong anticancer efficacy [21] . At targeting other cancer stem cells, some study has applied DC as a tool to target CSCs. By vaccination with DCs pulsed with the lysate of glioma stem cells, primed T cells were capable of selective targeting CSCs [12, 22] .
DCs pulsed with ALDH (high) CSC lysates induced significantly higher protective antitumor immunity than DCs pulsed with the lysates of unsorted whole tumor cell lysates in both melanoma and squamous cancer models [23] . Established CTL clones were analyzed using the IFN-γ ELISPOT assay, tumor antigen-loaded DCs induced significant IFN-γ production [24] . The study showed that DC vaccination using BSC lysates [25, 26] . The MHC-non-restricted immune cells, such as macrophages and NK cells. So, these cells, the only potentially able to recognize and eliminate MHC-non -expressing stem tumor cells [25] . Prostate stem cell antigen vaccinated TRAMP mice had a 90% survival rate at 12 months of age. In contrast, all control mice had succumbed to prostate cancer or had heavy tumor loads [26] . Several reports have described the killing of CSCs via nonspecific immune effector cells, such as natural killer cells [27] and γδ T lymphocytes [28] .
In summary, we explored the 
